Cargando…

Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines

Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease (IBD) which affects any site of the gastrointestinal tract and occasionally extraintestinal organs. The natural history of CD varies remarkably but a considerable proportion of patients develop complications leading to hospitali...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantzaris, Gerassimos J., Viazis, Nikos, Polymeros, Dimitris, Papamichael, Konstantinos, Bamias, George, Koutroubakis, Ioannis E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585386/
https://www.ncbi.nlm.nih.gov/pubmed/26424173
_version_ 1782392195328770048
author Mantzaris, Gerassimos J.
Viazis, Nikos
Polymeros, Dimitris
Papamichael, Konstantinos
Bamias, George
Koutroubakis, Ioannis E.
author_facet Mantzaris, Gerassimos J.
Viazis, Nikos
Polymeros, Dimitris
Papamichael, Konstantinos
Bamias, George
Koutroubakis, Ioannis E.
author_sort Mantzaris, Gerassimos J.
collection PubMed
description Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease (IBD) which affects any site of the gastrointestinal tract and occasionally extraintestinal organs. The natural history of CD varies remarkably but a considerable proportion of patients develop complications leading to hospitalizations and surgeries, impaired quality of life, and disability. In these patients, effective medical therapy should aim beyond control of clinical symptoms to include induction and maintenance of steroid-free clinical and serological remission and mucosal healing, as this has shown to reduce complications, hospitalizations and surgeries, and to decrease the risk of colorectal cancer, at least in the short term. This therapeutic goal can be achieved in a considerable proportion of patients with anti-tumor necrosis factor (TNF)-α agents if applied early in the disease course. Clinical recommendations from a panel of Greek IBD experts are herein provided, regarding the clinical profiles and the use of anti-TNF-α therapy in patients with moderate and severe CD, based on literature review and personal experience. The objectives of this advisory workshop were to define the profiles of patients with moderate and severe CD using routine clinical and laboratory parameters, as well as the clinical profiles of patients with moderate CD, severe CD, perianal CD, and/or extra-intestinal manifestations, who are candidates for biologic therapies. Emphasis was given on patients with newly diagnosed CD. The proposed recommendations may provide a useful and practical approach for improving therapeutic strategies with anti-TNF-α in patients with active moderate and severe CD.
format Online
Article
Text
id pubmed-4585386
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-45853862015-10-01 Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines Mantzaris, Gerassimos J. Viazis, Nikos Polymeros, Dimitris Papamichael, Konstantinos Bamias, George Koutroubakis, Ioannis E. Ann Gastroenterol Special Article Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease (IBD) which affects any site of the gastrointestinal tract and occasionally extraintestinal organs. The natural history of CD varies remarkably but a considerable proportion of patients develop complications leading to hospitalizations and surgeries, impaired quality of life, and disability. In these patients, effective medical therapy should aim beyond control of clinical symptoms to include induction and maintenance of steroid-free clinical and serological remission and mucosal healing, as this has shown to reduce complications, hospitalizations and surgeries, and to decrease the risk of colorectal cancer, at least in the short term. This therapeutic goal can be achieved in a considerable proportion of patients with anti-tumor necrosis factor (TNF)-α agents if applied early in the disease course. Clinical recommendations from a panel of Greek IBD experts are herein provided, regarding the clinical profiles and the use of anti-TNF-α therapy in patients with moderate and severe CD, based on literature review and personal experience. The objectives of this advisory workshop were to define the profiles of patients with moderate and severe CD using routine clinical and laboratory parameters, as well as the clinical profiles of patients with moderate CD, severe CD, perianal CD, and/or extra-intestinal manifestations, who are candidates for biologic therapies. Emphasis was given on patients with newly diagnosed CD. The proposed recommendations may provide a useful and practical approach for improving therapeutic strategies with anti-TNF-α in patients with active moderate and severe CD. Hellenic Society of Gastroenterology 2015 /pmc/articles/PMC4585386/ /pubmed/26424173 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Article
Mantzaris, Gerassimos J.
Viazis, Nikos
Polymeros, Dimitris
Papamichael, Konstantinos
Bamias, George
Koutroubakis, Ioannis E.
Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title_full Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title_fullStr Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title_full_unstemmed Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title_short Clinical profiles of moderate and severe Crohn’s disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines
title_sort clinical profiles of moderate and severe crohn’s disease patients and use of anti-tumor necrosis factor agents: greek expert consensus guidelines
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585386/
https://www.ncbi.nlm.nih.gov/pubmed/26424173
work_keys_str_mv AT mantzarisgerassimosj clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines
AT viazisnikos clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines
AT polymerosdimitris clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines
AT papamichaelkonstantinos clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines
AT bamiasgeorge clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines
AT koutroubakisioannise clinicalprofilesofmoderateandseverecrohnsdiseasepatientsanduseofantitumornecrosisfactoragentsgreekexpertconsensusguidelines